

**Shionogi announces its participation in an innovative new joint research initiative,  
The Cambridge Therapeutics Consortium**

---

**Osaka, Japan, February 15, 2016** – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President CEO: Isao Teshirogi, Ph.D.; hereinafter called “Shionogi”) announced today that it has joined the Cambridge Therapeutics Consortium. Launched in July 2015, the consortium links the intellectual know-how of several world renowned academic institutions with the drug developing potential of pharmaceutical industry.

The consortium unites the world leading research potential of the University of Cambridge and its partner institutions, the Babraham Institute and the Wellcome Trust Sanger Institute, with pharmaceutical companies, Astex Pharmaceuticals, Astra Zeneca, GlaxoSmithKline and Shionogi. The overarching aim for this innovative partnership model is to study and develop precision medicines for some of the most globally devastating diseases.

Researchers at the University of Cambridge (UK) and its partner institutions can access novel therapeutic agents (including small molecules and antibodies) across the entire portfolio of drugs being developed by each of the participating companies, enabling them to investigate their mechanism, efficacy and potential. The terms of the consortium allow researchers to access and share information quickly and easily. Funding is provided for joint research projects and the results of these collaborative projects will lead to joint publications supporting a culture of open innovation and partnership.

Professor Tony Kouzarides, Director of the Cambridge Therapeutics Consortium, “We are very excited to welcome Shionogi into this new venture and to work with them towards better patient care”

Dr. Takeshi Shiota, Corporate Officer and Senior Vice President at Shionogi Pharmaceutical Research Division, “As a pharmaceutical company which has strengths in small molecule drug discovery, we are proud to be part of the exciting new innovative approach to leveraging each other’s strengths and creating something new together”

Shionogi has continuously supplied superior medicines to people everywhere and constantly strives to identify promising research seeds and develop them into pharmaceuticals.

About Shionogi & Co., Ltd.

Shionogi & Co., Ltd. is a major research-driven pharmaceutical company dedicated to placing the highest value on patients based on its corporate philosophy of “supply the best possible medicine to protect the health and wellbeing of the patients we serve,” Shionogi’s research and development currently targets two therapeutic areas: infectious diseases and pain/CNS disorders. In addition to in-house research activity, Shionogi is focusing on utilization of outer resources from collaborative research with partners such as academia and other companies. Contributing to the health and QOL of patients around the world is Shionogi’s primary goal. For more details, please visit [www.shionogi.co.jp/en](http://www.shionogi.co.jp/en).

**Forward-Looking Statements**

*This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, unavailability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.*

**For further information, contact:**

Corporate Communications Department

Shionogi &amp; Co., Ltd.

Osaka Tel: +81-6-6209-7885 Fax: +81-6-6229-9596

Tokyo Tel: +81-3-3406-8164 Fax: +81-3-3406-8099